How Solar Power Brings Benefits to Commercial Roofs

 

Solar power, particularly on the roofs of commercial buildings, is obviously a way to promote sustainability – but what other benefits and incentives exist for companies looking to make the switch?

On this episode of Rook Talks, a Fortis Warranty podcast, New Columbia Solar CEO Mike Healy joined Voice of B2B Daniel Litwin to break down exactly what commercial operations can expect from going solar.

New Columbia Solar is the largest solar developer in Washington D.C., bringing solar energy to buildings across the spectrum, from commercial and industrial spaces to multi-family, non-profit and faith-based properties.

In D.C., incentives for solar installation are aimed at helping the district achieve 100%-clean power by 2032 and include sellable solar renewable energy credits that allow companies like New Columbia to receive capital in return to be used to finance solar systems, among other incentives.

Opportunities also exist for building owners to leverage solar roofing in renovations, Healy said.

“Any time that you’re looking at a roof replacement, you should be looking at solar at the same time,” he said. “The two should be conceived of together. It makes everything a lot easier and less costly. … If you have a building where you’re using the electricity within that building, meaning you’re operating that building and consuming power from within that building, you should absolutely be looking at using solar. It’s likely going to reduce your electricity costs.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More